Pharmacologic Upregulation of Cancer Testis Antigens Followed by Vaccine Therapy for Patients With Relapsed Acute Myelogenous Leukemia (AML) Following Allogeneic Stem Cell Transplantation

Trial Profile

Pharmacologic Upregulation of Cancer Testis Antigens Followed by Vaccine Therapy for Patients With Relapsed Acute Myelogenous Leukemia (AML) Following Allogeneic Stem Cell Transplantation

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 11 May 2017

At a glance

  • Drugs Decitabine (Primary) ; Cancer vaccine; Dendritic cell vaccines; Dendritic cells
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jun 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, as reported by ClinicalTRials.gov record.
    • 10 Dec 2013 Planned end date changed from 1 Mar 2016 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 10 Dec 2013 Planned number of patients changed from 13 to 10 and planned initiation date 1 Feb 2014 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top